Result of AGM

RNS Number : 9222S
Venn Life Sciences Holdings PLC
28 June 2018
 

 

28 June 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Result of AGM

 

Venn Life Sciences (AIM: VENN), an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device clients, that at the Company's Annual General Meeting held yesterday, all but resolution 6 of the resolutions put to the meeting were duly passed. Resolution 6 was a special resolution requiring 75 per cent. of votes cast to be in favour in order to be passed and sought the approval of shareholders to the dis-application of pre-emption rights to allot and issue new ordinary share for cash, per section 561 of the Companies Act 2006.

 

 

Enquiries:

 

Venn Life Sciences Holdings Plc

Tel: +353 154 99 341

Allan Wood, Non-Executive Chairman


Tony Richardson, Chief Executive Officer




Cenkos (Nominated Adviser and Co-Broker

Tel: +44 (0) 20 7397 8900 

Mark Connelly/Steve Cox (Corporate Finance)




Davy (Nominated Adviser, ESM Adviser and Joint Broker)

Tel: +353 1 679 6363

Fergal Meegan / Matthew DeVere White (Corporate Finance)


Paul Burke (Corporate Broking)




Hybridan LLP (Joint-Broker)

               

Claire Louise Noyce

Tel: 020 3764 2341



Walbrook PR Ltd

Tel: 020 7933 8780 or venn@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Paul McManus

Mob: 07980 541 893

 

 

 

About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

For more information about the Company, please visit: www.vennlifesciences.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGUWSRRWOANUAR

Companies

Hvivo (HVO)
UK 100

Latest directors dealings